Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post–2021 Guidelines: Are Economic Barriers Finally Coming Down?,Clinical Infectious Diseases

当前位置： X-MOL 学术 › Clin. Infect. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post–2021 Guidelines: Are Economic Barriers Finally Coming Down?
Clinical Infectious Diseases ( IF 11.8 ) Pub Date : 2021-12-30 , DOI: 10.1093/cid/ciab1061
Noah Fang ₁ , David Ha _{2,

3,

4} , Kimberly Dong ₁ , Thomas Leung ₁ , Sydney Lee ₁ , Marisa Holubar _{3,

4} , Lina Meng _{2,

3,

4}

Affiliation

We reviewed Clostridioides difficile–positive patients discharged on fidaxomicin after local adoption of 2021 C. difficile infection (CDI) guidelines. From 14 June to 3 October 2021, 80% (12/15) had copayments of $0–$35 and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.

中文翻译：

艰难梭菌感染成年患者成功出院非达霉素 2021 年后指南：经济障碍最终会消失吗？

我们审查了在当地采用 2021 年艰难梭菌感染 (CDI) 指南后出院并服用非达霉素的艰难梭菌阳性患者。从 2021 年 6 月 14 日到 10 月 3 日，80% (12/15) 的共付额为 0-35 美元，27% (4/15) 需要事先授权。30 天的 CDI 复发率为 7%。

更新日期：2021-12-30

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>